Vabysmo is a bispecific antibody designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the ...

A new clinical study published in the Romanian Journal of Ophthalmology revealed that low-dose atorvastatin (10–20 mg) used ...

Valiltramiprosate is associated with low ARIA rates and is well tolerated in APOE ε4 homozygotes with early Alzheimer disease ...

Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has completed ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing investigational therapies for patients with Alzheimer’s ...

Three world-leading key opinion leaders, researchers and clinicians, join Clinical Advisory Board, reinforcing Bioxodes' global registrational clinical strategy -- Positive ongoing discussions with ...

Less than 24 hours after throwing 4 1/3 innings in his minor league rehabilitation start for Double-A Somerset, New York ...

Eclipse Life Sciences begins phase 2 study for novel ophthalmology steroid implant for diabetic macular edema: Research Triangle Park, North Carolina Tuesday, April 14, 2026, 18:0 ...

Yankees ace Gerrit Cole gave up three runs over 4 1/3 innings for Double-A Somerset in his first minor league rehabilitation ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

El derecho de los Yankees, Gerrit Cole, lanzará alrededor de 45 pitcheos en su primera apertura de rehabilitación por lesión ...